Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.
about
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersChallenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridizationTesting for HER2-positive breast cancer: a systematic review and cost-effectiveness analysisTrastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan.Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence.Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.The costs of colonoscopy in a Canadian hospital using a microcosting approach
P2860
Q22330767-E9A96B5A-9723-4EDE-83AC-88FAAA18A138Q34022038-0000EB5A-D76A-4F67-9BD2-CFED62E01E52Q34071408-46DC4DB3-E089-4F39-9230-82DEC53050B6Q35778406-C71E4EF1-C788-445F-94ED-4642466D904FQ35891822-D9C3F7ED-F18D-4320-881C-72F64B319EDCQ36307517-37546D80-89F9-4E79-B443-E342E3ADE021Q36381274-D8B4B89A-310D-4BBC-9D42-0F541A7709B3Q37385536-BAAB8171-41DB-4297-82F4-F258E9766013Q38084203-F804A73F-E37E-46A7-808A-9951DE11F2B3Q38153808-C699F91B-3E0D-462D-94A7-F2404AC74107Q38241709-6659865D-EAF6-483F-9F0D-1E31CEDC5100Q42005633-2C691C7F-291C-4856-A10F-418EA5A1185D
P2860
Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cost-effectiveness of Hercepti ...... a Belgian university hospital.
@en
type
label
Cost-effectiveness of Hercepti ...... a Belgian university hospital.
@en
prefLabel
Cost-effectiveness of Hercepti ...... a Belgian university hospital.
@en
P2093
P2860
P1476
Cost-effectiveness of Hercepti ...... a Belgian university hospital.
@en
P2093
Bart Clarysse
Johan A Albrecht
Mattias J Neyt
Véronique F Cocquyt
P2860
P304
P356
10.1017/S0266462305050178
P577
2005-01-01T00:00:00Z